PMID- 34481515
OWN - NLM
STAT- MEDLINE
DCOM- 20210907
LR  - 20220531
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 14
IP  - 1
DP  - 2021 Sep 4
TI  - Effect of the uncoupling protein-2 (UCP-2) and nuclear receptor subfamily 3 group 
      C member 1 (NR3C1) genes on treatment efficacy and survival in patients with 
      multiple myeloma: a single-center study.
PG  - 346
LID - 10.1186/s13104-021-05758-7 [doi]
LID - 346
AB  - OBJECTIVE: Studies on the genetic background of patients with multiple myeloma 
      (MM) have been increasing; two important factors considered in such works are 
      uncoupling protein-2 (UCP-2) and nuclear receptor subfamily 3 group C member 1 
      (NR3C1). We aim to reveal the association of MM with NR3C1 and UCP-2 gene 
      polymorphisms. In this prospective study, 200 patients diagnosed between January 
      2009 and 2018 and 200 healthy individuals were included. For patients who had 
      undergone autologous stem cell transplantation and control subjects, we 
      statistically compared the CC, GC, and GG genotypes and the C and G alleles of 
      the NR3C1 gene, as well as the AA, AG, and GG genotypes and the A and G alleles 
      of the UCP-2 gene. RESULTS: While the AA genotype was significantly more common 
      in the MM group (p = 0.001), the GG genotype was significantly more common in the 
      control group (p = 0.016). Overall survival was found to be significantly shorter 
      in patients with the UCP-2 GG genotype (p = 0.034). It was also found that having 
      the GG genotype of the UCP-2 gene was a 2.48-fold risk factor for mortality. The 
      fact that overall survival is significantly shorter in MM patients with the UCP-2 
      GG genotype and its definition as a risk factor for mortality have been put 
      forward for the first time in the literature.
CI  - (c) 2021. The Author(s).
FAU - Demir, Ilknur
AU  - Demir I
AD  - Department of Internal Medicine, Faculty of Medicine, Gaziantep University, 
      Gaziantep, Turkey.
FAU - Pehlivan, Sacide
AU  - Pehlivan S
AD  - Department of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, 
      Istanbul, Turkey.
FAU - Okan, Vahap
AU  - Okan V
AD  - Department of Hematology, Faculty of Medicine, Gaziantep University, Gaziantep, 
      Turkey.
FAU - Sahin, Handan Haydaroglu
AU  - Sahin HH
AD  - Department of Hematology, Faculty of Medicine, Gaziantep University, Gaziantep, 
      Turkey.
FAU - Durusoy, Salih Sertac
AU  - Durusoy SS
AD  - Department of Hematology, Faculty of Medicine, Gaziantep University, Gaziantep, 
      Turkey.
FAU - Serin, Istemi
AU  - Serin I
AUID- ORCID: 0000-0003-1855-774X
AD  - Department of Hematology, University of Health Sciences, Istanbul Training and 
      Research Hospital, Org. Nafiz Gurman Cad., Fatih, 34098, Istanbul, Turkey. 
      serinistemi@hotmail.com.
FAU - Oyaci, Yasemin
AU  - Oyaci Y
AD  - Department of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, 
      Istanbul, Turkey.
FAU - Pehlivan, Mustafa
AU  - Pehlivan M
AD  - Department of Hematology, Faculty of Medicine, Gaziantep University, Gaziantep, 
      Turkey.
AD  - Department of Hematology, University of Health Sciences, Istanbul Training and 
      Research Hospital, Org. Nafiz Gurman Cad., Fatih, 34098, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20210904
PL  - England
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
RN  - 0 (NR3C1 protein, human)
RN  - 0 (Receptors, Glucocorticoid)
RN  - 0 (UCP2 protein, human)
RN  - 0 (Uncoupling Protein 2)
SB  - IM
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - *Multiple Myeloma/genetics/therapy
MH  - Polymorphism, Single Nucleotide
MH  - Prospective Studies
MH  - *Receptors, Glucocorticoid/genetics
MH  - Transplantation, Autologous
MH  - Treatment Outcome
MH  - *Uncoupling Protein 2/genetics
PMC - PMC8418283
OTO - NOTNLM
OT  - Autologous stem cell transplantation
OT  - Multiple myeloma
OT  - NR3C1
OT  - Overall survival
OT  - Prognosis
OT  - UCP-2
COIS- The authors declare that they have no competing interests.
EDAT- 2021/09/06 06:00
MHDA- 2021/09/08 06:00
PMCR- 2021/09/04
CRDT- 2021/09/05 20:23
PHST- 2021/03/03 00:00 [received]
PHST- 2021/08/23 00:00 [accepted]
PHST- 2021/09/05 20:23 [entrez]
PHST- 2021/09/06 06:00 [pubmed]
PHST- 2021/09/08 06:00 [medline]
PHST- 2021/09/04 00:00 [pmc-release]
AID - 10.1186/s13104-021-05758-7 [pii]
AID - 5758 [pii]
AID - 10.1186/s13104-021-05758-7 [doi]
PST - epublish
SO  - BMC Res Notes. 2021 Sep 4;14(1):346. doi: 10.1186/s13104-021-05758-7.